Cargando…

Cefiderocol-Based Combination Therapy for “Difficult-to-Treat” Gram-Negative Severe Infections: Real-Life Case Series and Future Perspectives

Cefiderocol is a new cephalosporin displaying against extensively resistant (XDR) Gram-negative bacteria. We report our experience with cefiderocol-based combination therapies as “rescue” treatments in immunocompromised or critically ill patients or in patients with post-surgical infections who had...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bavaro, Davide Fiore, Belati, Alessandra, Diella, Lucia, Stufano, Monica, Romanelli, Federica, Scalone, Luca, Stolfa, Stefania, Ronga, Luigi, Maurmo, Leonarda, Dell’Aera, Maria, Mosca, Adriana, Dalfino, Lidia, Grasso, Salvatore, Saracino, Annalisa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8227820/ https://www.ncbi.nlm.nih.gov/pubmed/34072342 http://dx.doi.org/10.3390/antibiotics10060652

Ejemplares similares

Cefiderocol Versus Colistin for the Treatment of Carbapenem-Resistant Acinetobacter baumannii Complex Bloodstream Infections: A Retrospective, Propensity-Score Adjusted, Monocentric Cohort Study
por: Bavaro, Davide Fiore, et al.
Publicado: (2023)

Effectiveness of First-Line Therapy with Old and Novel Antibiotics in Ventilator-Associated Pneumonia Caused by Carbapenem-Resistant Acinetobacter baumannii: A Real Life, Prospective, Observational, Single-Center Study
por: Dalfino, Lidia, et al.
Publicado: (2023)

Coinfections in intensive care units. Has anything changed with Covid-19 pandemia?
por: Romanelli, Federica, et al.
Publicado: (2023)

Meropenem/Vaborbactam Plus Aztreonam as a Possible Treatment Strategy for Bloodstream Infections Caused by Ceftazidime/Avibactam-Resistant Klebsiella pneumoniae: A Retrospective Case Series and Literature Review
por: Belati, Alessandra, et al.
Publicado: (2022)

Impact of a Multistep Bundles Intervention in the Management and Outcome of Gram-Negative Bloodstream Infections: A Single-Center “Proof-of-Concept” Study
por: Bavaro, Davide Fiore, et al.
Publicado: (2022)

Dalbavancin Efficacy and Impact on Hospital Length-of-Stay and Treatment Costs in Different Gram-Positive Bacterial Infections
por: Poliseno, Mariacristina, et al.
Publicado: (2021)

Stenotrophomonas maltophilia Infections: A Systematic Review and Meta-Analysis of Comparative Efficacy of Available Treatments, with Critical Assessment of Novel Therapeutic Options
por: Maraolo, Alberto Enrico, et al.
Publicado: (2023)

Efficacy of Remdesivir and Neutralizing Monoclonal Antibodies in Monotherapy or Combination Therapy in Reducing the Risk of Disease Progression in Elderly or Immunocompromised Hosts Hospitalized for COVID-19: A Single Center Retrospective Study
por: Bavaro, Davide Fiore, et al.
Publicado: (2023)

648. Cefiderocol as Rescue Therapy for Pseudomonas aeruginosa and Other Difficult-To-Treat Gram-Negative Infections
por: Chou, Andrew, et al.
Publicado: (2022)

Bamlanivimab and Etesevimab administered in an outpatient setting for SARS-CoV-2 infection
por: Bavaro, DF, et al.
Publicado: (2022)

Occurrence of Acute Pulmonary Embolism in COVID-19—A case series
por: Bavaro, Davide Fiore, et al.
Publicado: (2020)

Prompt and Appropriate Antimicrobial Therapy Improves Outcomes of NDM-Producing and KPC-Producing Klebsiella pneumoniae Bloodstream Infections in Patients Hospitalized for COVID-19: A Comparative Retrospective Case-Series
por: Bavaro, Davide Fiore, et al.
Publicado: (2022)

Impact of a Pro-Active Infectious Disease Consultation on the Management of a Multidrug-Resistant Organisms Outbreak in a COVID-19 Hospital: A Three-Months Quasi-Experimental Study
por: Bavaro, Davide Fiore, et al.
Publicado: (2023)

Incidence of long COVID-19 in people with previous SARS-Cov2 infection: a systematic review and meta-analysis of 120,970 patients
por: Di Gennaro, Francesco, et al.
Publicado: (2022)

Impact of Vitamin D in Prophylaxis and Treatment in Tuberculosis Patients
por: Papagni, Roberta, et al.
Publicado: (2022)

Analysis of Italian requests for compensation in cases of responsibility for healthcare-related infections: A retrospective study
por: Marrone, Maricla, et al.
Publicado: (2023)

Cefiderocol: A Review in Serious Gram-Negative Bacterial Infections
por: Syed, Yahiya Y.
Publicado: (2021)

P35 Heteroresistance to cefiderocol in clinical Gram-negative isolates
por: Watson, Celeste, et al.
Publicado: (2023)

Predictors for Pulmonary Tuberculosis Outcome and Adverse Events in an Italian Referral Hospital: A Nine-Year Retrospective Study (2013–2021)
por: Di Gennaro, Francesco, et al.
Publicado: (2022)

First Case of Paraphimosis as a Severe Complication of Monkeypox
por: Milano, Eugenio, et al.
Publicado: (2022)

Correction to: Cefiderocol: A Review in Serious Gram-Negative Bacterial Infections
por: Syed, Yahiya Y.
Publicado: (2021)

Cefiderocol Retains Antibiofilm Activity in Multidrug-Resistant Gram-Negative Pathogens
por: Pybus, Christine A., et al.
Publicado: (2021)

Performance evaluation of the UMIC(®) Cefiderocol to determine MIC in Gram-negative bacteria
por: Dortet, Laurent, et al.
Publicado: (2023)

The Burden of the Serious and Difficult-to-Treat Infections and a New Antibiotic Available: Cefiderocol
por: Taheri, Yasaman, et al.
Publicado: (2021)

Cefiderocol: A Novel Agent for the Management of Multidrug-Resistant Gram-Negative Organisms
por: Wu, Janet Y., et al.
Publicado: (2020)

719. Cefiderocol Retains Anti-Biofilm Activity in MDR Gram-Negative Pathogens
por: Pybus, Christine A, et al.
Publicado: (2019)

Susceptibility of cefiderocol and other antibiotics against carbapenem-resistant, Gram-negative bacteria
por: Wang, Yifan, et al.
Publicado: (2022)

Cefiderocol, a new antibiotic against multidrug-resistant Gram-negative bacteria
por: Silva, José Tiago, et al.
Publicado: (2021)

Case series of cefiderocol for salvage therapy in carbapenem-resistant Gram-negative infections
por: Gavaghan, Victoria, et al.
Publicado: (2022)

Potential Role of Vitamins A, B, C, D and E in TB Treatment and Prevention: A Narrative Review
por: Patti, Giulia, et al.
Publicado: (2021)

Cefiderocol Treatment for Severe Infections due to Difficult-to-Treat-Resistant Non-Fermentative Gram-Negative Bacilli in ICU Patients: A Case Series and Narrative Literature Review
por: Wicky, Paul-Henri, et al.
Publicado: (2023)

Daptomycin versus Vancomycin for the Treatment of Methicillin-Resistant Staphylococcus aureus Bloodstream Infection with or without Endocarditis: A Systematic Review and Meta-Analysis
por: Maraolo, Alberto Enrico, et al.
Publicado: (2021)

Cefiderocol
por: Soriano, María Cruz, et al.
Publicado: (2022)

660. In vitro activity of cefiderocol against difficult-to-treat resistance European Gram-negative bacterial pathogens from the multi-national sentinel surveillance study, SENTRY in 2020 and 2021
por: Santerre Henriksen, Anne Laurence, et al.
Publicado: (2022)

1715. In Vitro Antibacterial Activity of Cefiderocol against Difficult-to-treat Resistant (DTR) Gram-negative Pathogens in United States from SENTRY Antimicrobial Surveillance Program in 2020/2021
por: Yamano, Yoshinori, et al.
Publicado: (2022)

2762. Activity of Cefiderocol and Comparator Agents Against Difficult to Treat Resistance (DTR) Gram-negative Isolates, Collected During 2020-2022 as Part of SENTRY Antimicrobial Surveillance Program
por: DeJonge, Boudewijn L, et al.
Publicado: (2023)

Guinea Worm Disease: A Neglected Diseases on the Verge of Eradication
por: Pellegrino, Carmen, et al.
Publicado: (2022)

Remote vs in-person BRCA1/2 non-carriers test disclosure: patients’ choice during Covid-19 pandemic restriction
por: Costanzo, Silvia, et al.
Publicado: (2022)

In Vitro Antibacterial Properties of Cefiderocol, a Novel Siderophore Cephalosporin, against Gram-Negative Bacteria
por: Ito, Akinobu, et al.
Publicado: (2017)

In Vitro Activity of Cefiderocol against Multi-Drug Resistant Carbapenemase-Producing Gram-Negative Pathogens
por: Boyd, Sandra, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_093o4dctg6qv2j43obk3487kll